ATE384521T1 - Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen - Google Patents

Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen

Info

Publication number
ATE384521T1
ATE384521T1 AT01924057T AT01924057T ATE384521T1 AT E384521 T1 ATE384521 T1 AT E384521T1 AT 01924057 T AT01924057 T AT 01924057T AT 01924057 T AT01924057 T AT 01924057T AT E384521 T1 ATE384521 T1 AT E384521T1
Authority
AT
Austria
Prior art keywords
treatment
parasitic protozoa
disease
trypanosomiasis
medicine
Prior art date
Application number
AT01924057T
Other languages
English (en)
Inventor
Anders Hofer
Lars Thelander
Original Assignee
Anders Hofer
Lars Thelander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anders Hofer, Lars Thelander filed Critical Anders Hofer
Application granted granted Critical
Publication of ATE384521T1 publication Critical patent/ATE384521T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01924057T 2000-04-27 2001-04-20 Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen ATE384521T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001531A SE0001531D0 (sv) 2000-04-27 2000-04-27 Medicament for the treatment of diseases caused by parasiticprotozoa

Publications (1)

Publication Number Publication Date
ATE384521T1 true ATE384521T1 (de) 2008-02-15

Family

ID=20279443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01924057T ATE384521T1 (de) 2000-04-27 2001-04-20 Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen

Country Status (8)

Country Link
US (1) US7157449B2 (de)
EP (1) EP1284725B1 (de)
AT (1) ATE384521T1 (de)
AU (1) AU2001250722A1 (de)
DE (1) DE60132581T2 (de)
ES (1) ES2298229T3 (de)
SE (1) SE0001531D0 (de)
WO (1) WO2001080809A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276438A1 (en) * 2004-10-04 2006-12-07 Natarajan Sethuraman Prevention and treatment of influenza with glutamine antagonist agents
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
WO2016201307A1 (en) * 2015-06-12 2016-12-15 The United State of America, as represented by the Secretary, Dept. of Health and Human Services Glutamine antagonists for use in treating cerebral edema and cerebral malaria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000081A2 (en) * 1989-06-21 1991-01-10 The Catholic University Of America Anti-malarial composition and method of use
US5180714A (en) * 1990-10-31 1993-01-19 Health Research, Inc. Adenosine compounds for the treatment of diseases caused by parasitic protozoa
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
AU5825598A (en) 1997-01-21 1998-08-07 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced suppression of hiv-1 by the combination of cytidine nucleoside analogues and ctp synthase inhibitors

Also Published As

Publication number Publication date
AU2001250722A1 (en) 2001-11-07
DE60132581D1 (de) 2008-03-13
US7157449B2 (en) 2007-01-02
WO2001080809A3 (en) 2002-02-28
US20030109505A1 (en) 2003-06-12
SE0001531D0 (sv) 2000-04-27
ES2298229T3 (es) 2008-05-16
DE60132581T2 (de) 2009-01-29
EP1284725B1 (de) 2008-01-23
EP1284725A2 (de) 2003-02-26
WO2001080809A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
DK0853083T3 (da) Pyridylfuran- og piridylthiophenforbindelser og farmaceutisk anvendelse deraf
PT1404347E (pt) Nucleosidos 4&#39;-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
HUP0303082A2 (hu) Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
DE60132581D1 (de) Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
MA27474A1 (fr) Vaccin
ATE386741T1 (de) Pyrazolamide zur behandlung von hiv-infektionen
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
HUP0401940A2 (hu) Diabetikus neuropátia esetében alkalmazható gyógyszerkészítmény
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
DK1451184T3 (da) Dimere forbindelser og deres anvendelse som antivirale midler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties